These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

423 related items for PubMed ID: 17581625

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. The genetics and biology of Irf5-mediated signaling in lupus.
    Kozyrev SV, Alarcon-Riquelme ME.
    Autoimmunity; 2007 Dec; 40(8):591-601. PubMed ID: 18075793
    [Abstract] [Full Text] [Related]

  • 4. Type I interferon in systemic lupus erythematosus and other autoimmune diseases.
    Banchereau J, Pascual V.
    Immunity; 2006 Sep; 25(3):383-92. PubMed ID: 16979570
    [Abstract] [Full Text] [Related]

  • 5. Toll-like receptor activation in the pathogenesis of systemic lupus erythematosus.
    Means TK, Luster AD.
    Ann N Y Acad Sci; 2005 Dec; 1062():242-51. PubMed ID: 16461805
    [Abstract] [Full Text] [Related]

  • 6. TLR9/TLR7-triggered downregulation of BDCA2 expression on human plasmacytoid dendritic cells from healthy individuals and lupus patients.
    Wu P, Wu J, Liu S, Han X, Lu J, Shi Y, Wang J, Lu L, Cao X.
    Clin Immunol; 2008 Oct; 129(1):40-8. PubMed ID: 18684674
    [Abstract] [Full Text] [Related]

  • 7. A common haplotype of interferon regulatory factor 5 (IRF5) regulates splicing and expression and is associated with increased risk of systemic lupus erythematosus.
    Graham RR, Kozyrev SV, Baechler EC, Reddy MV, Plenge RM, Bauer JW, Ortmann WA, Koeuth T, González Escribano MF, Argentine and Spanish Collaborative Groups, Pons-Estel B, Petri M, Daly M, Gregersen PK, Martín J, Altshuler D, Behrens TW, Alarcón-Riquelme ME.
    Nat Genet; 2006 May; 38(5):550-5. PubMed ID: 16642019
    [Abstract] [Full Text] [Related]

  • 8. Comprehensive evaluation of the genetic variants of interferon regulatory factor 5 (IRF5) reveals a novel 5 bp length polymorphism as strong risk factor for systemic lupus erythematosus.
    Sigurdsson S, Göring HH, Kristjansdottir G, Milani L, Nordmark G, Sandling JK, Eloranta ML, Feng D, Sangster-Guity N, Gunnarsson I, Svenungsson E, Sturfelt G, Jönsen A, Truedsson L, Barnes BJ, Alm G, Rönnblom L, Syvänen AC.
    Hum Mol Genet; 2008 Mar 15; 17(6):872-81. PubMed ID: 18063667
    [Abstract] [Full Text] [Related]

  • 9. Expression of the markers BDCA-2 and BDCA-4 and production of interferon-alpha by plasmacytoid dendritic cells in systemic lupus erythematosus.
    Blomberg S, Eloranta ML, Magnusson M, Alm GV, Rönnblom L.
    Arthritis Rheum; 2003 Sep 15; 48(9):2524-32. PubMed ID: 13130472
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Induction of interferon-alpha production in plasmacytoid dendritic cells by immune complexes containing nucleic acid released by necrotic or late apoptotic cells and lupus IgG.
    Lövgren T, Eloranta ML, Båve U, Alm GV, Rönnblom L.
    Arthritis Rheum; 2004 Jun 15; 50(6):1861-72. PubMed ID: 15188363
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Association of a common interferon regulatory factor 5 (IRF5) variant with increased risk of systemic lupus erythematosus (SLE).
    Demirci FY, Manzi S, Ramsey-Goldman R, Minster RL, Kenney M, Shaw PS, Dunlop-Thomas CM, Kao AH, Rhew E, Bontempo F, Kammerer C, Kamboh MI.
    Ann Hum Genet; 2007 May 15; 71(Pt 3):308-11. PubMed ID: 17166181
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. IRF5-mediated signaling and implications for SLE.
    Lazzari E, Jefferies CA.
    Clin Immunol; 2014 Aug 15; 153(2):343-52. PubMed ID: 24928322
    [Abstract] [Full Text] [Related]

  • 17. Statins, inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase, function as inhibitors of cellular and molecular components involved in type I interferon production.
    Amuro H, Ito T, Miyamoto R, Sugimoto H, Torii Y, Son Y, Nakamichi N, Yamazaki C, Hoshino K, Kaisho T, Ozaki Y, Inaba M, Amakawa R, Fukuhara S.
    Arthritis Rheum; 2010 Jul 15; 62(7):2073-85. PubMed ID: 20506142
    [Abstract] [Full Text] [Related]

  • 18. Type I interferon-associated cytotoxic inflammation in cutaneous lupus erythematosus.
    Wenzel J, Zahn S, Bieber T, Tüting T.
    Arch Dermatol Res; 2009 Jan 15; 301(1):83-6. PubMed ID: 18784932
    [Abstract] [Full Text] [Related]

  • 19. Structural insertion/deletion variation in IRF5 is associated with a risk haplotype and defines the precise IRF5 isoforms expressed in systemic lupus erythematosus.
    Kozyrev SV, Lewén S, Reddy PM, Pons-Estel B, Argentine Collaborative Group, Witte T, German Collaborative Group, Junker P, Laustrup H, Gutiérrez C, Suárez A, Francisca González-Escribano M, Martín J, Spanish Collaborative Group, Alarcón-Riquelme ME.
    Arthritis Rheum; 2007 Apr 15; 56(4):1234-41. PubMed ID: 17393452
    [Abstract] [Full Text] [Related]

  • 20. PTPN22 Variant R620W Is Associated With Reduced Toll-like Receptor 7-Induced Type I Interferon in Systemic Lupus Erythematosus.
    Wang Y, Ewart D, Crabtree JN, Yamamoto A, Baechler EC, Fazeli P, Peterson EJ.
    Arthritis Rheumatol; 2015 Sep 15; 67(9):2403-14. PubMed ID: 26018863
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.